Krystal Biotech (KRYS) Competitors $125.05 -0.24 (-0.19%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$125.04 -0.01 (-0.01%) As of 05/23/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KRYS vs. ITCI, GMAB, RDY, VTRS, MRNA, ASND, QGEN, ROIV, RVMD, and ELANShould you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Krystal Biotech vs. Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Viatris Moderna Ascendis Pharma A/S Qiagen Roivant Sciences Revolution Medicines Elanco Animal Health Krystal Biotech (NASDAQ:KRYS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations. Does the media refer more to KRYS or ITCI? In the previous week, Krystal Biotech had 9 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 10 mentions for Krystal Biotech and 1 mentions for Intra-Cellular Therapies. Krystal Biotech's average media sentiment score of 1.40 beat Intra-Cellular Therapies' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KRYS or ITCI? Krystal Biotech currently has a consensus price target of $211.13, indicating a potential upside of 68.83%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Krystal Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Krystal Biotech is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has higher valuation and earnings, KRYS or ITCI? Krystal Biotech has higher earnings, but lower revenue than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$333.45M10.84$10.93M$4.1630.06Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the MarketBeat Community believe in KRYS or ITCI? Intra-Cellular Therapies received 223 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 67.80% of users gave Krystal Biotech an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformKrystal BiotechOutperform Votes29967.80% Underperform Votes14232.20% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Which has more volatility & risk, KRYS or ITCI? Krystal Biotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Do insiders & institutionals have more ownership in KRYS or ITCI? 86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is KRYS or ITCI more profitable? Krystal Biotech has a net margin of 30.69% compared to Intra-Cellular Therapies' net margin of -14.07%. Krystal Biotech's return on equity of 11.41% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech30.69% 11.41% 10.40% Intra-Cellular Therapies -14.07%-9.93%-8.38% SummaryKrystal Biotech beats Intra-Cellular Therapies on 15 of the 19 factors compared between the two stocks. Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRYS vs. The Competition Export to ExcelMetricKrystal BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.61B$2.92B$5.34B$8.30BDividend YieldN/A1.63%5.27%4.11%P/E Ratio41.8231.0126.9619.59Price / Sales10.84418.26398.83135.98Price / Cash39.38168.6838.3234.64Price / Book3.813.236.774.50Net Income$10.93M-$72.35M$3.24B$248.60M7 Day Performance-4.25%1.84%0.27%-0.89%1 Month Performance-25.59%1.36%5.91%7.41%1 Year Performance-23.20%-25.04%18.83%8.56% Krystal Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRYSKrystal Biotech4.9091 of 5 stars$125.05-0.2%$211.13+68.8%-23.2%$3.61B$333.45M41.82210Positive NewsITCIIntra-Cellular Therapies0.6655 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S3.4132 of 5 stars$20.18+1.5%$39.17+94.1%-25.7%$12.75B$3.12B11.601,660News CoverageRDYDr. Reddy's Laboratories2.2955 of 5 stars$14.45+0.1%$17.00+17.6%+3.4%$12.06B$325.54B23.0124,800Positive NewsVTRSViatris2.7385 of 5 stars$8.76-0.9%$10.50+19.9%-20.4%$10.28B$14.33B-11.8437,000Trending NewsGap DownMRNAModerna4.4354 of 5 stars$26.39+6.2%$53.95+104.4%-84.2%$10.21B$3.14B-2.843,900Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeASNDAscendis Pharma A/S3.3446 of 5 stars$160.33+1.7%$216.07+34.8%+24.2%$9.78B$368.70M-22.58640Positive NewsQGENQiagen3.9817 of 5 stars$42.77+0.3%$48.42+13.2%-1.1%$9.51B$2.00B119.096,030Positive NewsROIVRoivant Sciences1.9073 of 5 stars$10.84+0.5%$17.50+61.4%-1.0%$7.73B$122.59M-72.26860Positive NewsUpcoming EarningsInsider TradeRVMDRevolution Medicines4.3494 of 5 stars$39.93+1.0%$67.08+68.0%+4.8%$7.44B$742,000.00-11.12250Positive NewsGap DownELANElanco Animal Health3.2152 of 5 stars$13.24+2.5%$15.17+14.6%-24.6%$6.58B$4.43B33.109,800Gap Up Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives RDY Alternatives VTRS Alternatives MRNA Alternatives ASND Alternatives QGEN Alternatives ROIV Alternatives RVMD Alternatives ELAN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRYS) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KRYS Stock Free KRYS Stock Alerts